The Enterprise Value as of September 2024 (TTM) for Fate Therapeutics, Inc. (FATE) is 449.69M

According to Fate Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 449.69M. This represents a change of -2.99% compared to the average of 463.56M of the last 4 quarters.

Fate Therapeutics, Inc. (FATE) Historical Enterprise Value (quarterly & annually)

How has FATE Enterprise Value performed in the past?

The mean historical Enterprise Value of Fate Therapeutics, Inc. over the last ten years is 1.65B. The current 449.69M Enterprise Value has changed 2.62% with respect to the historical average. Over the past ten years (40 quarters), FATE's Enterprise Value was at its highest in in the June 2021 quarter at 8.22B. The Enterprise Value was at its lowest in in the December 2016 quarter at 15.49M.

Fate Therapeutics, Inc. (FATE) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Fate Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Fate Therapeutics, Inc. (FATE) Average Enterprise Value

How has FATE Enterprise Value performed in the past?

The current Enterprise Value of Fate Therapeutics, Inc. (FATE) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Fate Therapeutics, Inc. (FATE) Enterprise Value vs. Peers

How is FATE’s Enterprise Value compared to its peers?

Fate Therapeutics, Inc.’s Enterprise Value is greater than Atara Biotherapeutics, Inc. (104.92M), less than Sana Biotechnology, Inc. (1.08B), greater than Caribou Biosciences, Inc. (144.89M), less than Arcus Biosciences, Inc. (1.29B), less than Intellia Therapeutics, Inc. (1.98B), greater than Editas Medicine, Inc. (270.35M), less than CRISPR Therapeutics AG (3.55B), greater than Verve Therapeutics, Inc. (404.46M), greater than Theseus Pharmaceuticals, Inc. (138.26M), greater than aTyr Pharma, Inc. (138.44M), less than Relay Therapeutics, Inc. (752.45M), greater than Century Therapeutics, Inc. (138.60M), less than Blueprint Medicines Corporation (6.16B), less than Beam Therapeutics Inc. (1.79B), greater than Prime Medicine, Inc. (412.09M),

Build a custom stock screener for Fate Therapeutics, Inc. (FATE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Fate Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Fate Therapeutics, Inc. (FATE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Fate Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.